Proof-of-Concept Trial Confirms ZT-01’s Mechanism of Action in Restoring Glucagon Release in Patients with Type 1 Diabetes First-in-Class ZT-01 has the Potential to Become the First Therapeutic to Prevent Hypoglycemia… Read More
Submission is based on pivotal Phase 3 PROGRESS chronic migraine study evaluating atogepant (QULIPTATM) in adult patients that met primary endpoint of statistically significant reduction from baseline in mean monthly… Read More
VANCOUVER, BC — Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage pharmaceutical development company, announces that patients from multiple sites participating… Read More
XEN1101 Phase 3 program for the treatment of focal onset seizures to be initiated in the second half of 2022 and New Drug Application expected to be submitted after completion… Read More
The accelerator aims to connect corporations with cleantech startups to advance climate innovation. MaRS Discovery District has partnered with KPMG Canada to launch the Climate Impact Accelerator. “While large corporations… Read More
